Luka Doncic (Dallas Mavericks) with a deep 3 vs the New York Knicks, 04/16/2021
Luka Doncic (Dallas Mavericks) with a deep 3 vs the New York Knicks, 04/16/2021
"I'm shocked that he's shocked."
The Board of Directors of Cummins Inc. (NYSE: CMI) today declared a quarterly common stock cash dividend of 1.35 dollars per share, payable on June 3, 2021, to shareholders of record on May 21, 2021.
New Delhi [India], May 12 (ANI): The flight operations from Terminal 2 (T2) of the Indira Gandhi International Airport in the national capital will be shifted to Terminal 3 (T3) from the intervening night of May 17-18 due to falling in passengers traffic amid the COVID-19 pandemic, informed officials on Tuesday.
Mets ace Jacob deGrom resumed playing catch and plans to evaluate his mechanics after New York placed him on the 10-day injured list Tuesday with tightness in his right side. Mets manager Luis Rojas said the team was unsure how the issue arose for deGrom, who is 3-2 with a major league-best 0.68 ERA along with 65 strikeouts in 40 innings.
A rainbow sidewalk will soon be in front of L.P. Miller, after Nipawin council passed a modified proposal by the school’s Gay-Straight Alliance to temporarily paint the surface. Last month, council rejected the previous variation of their proposal, despite passing a similar motion in 2020. The recommendation to reject it from the town’s Community Development Standing Committee who stated that painting sidewalks is a safety issue. The committee said that a number of people complained to the town, some of which alleged to have fallen due to walking on a painted surface. Another concern expressed was the difficulty with removing it. In this new proposal, the GSA gave three different options to the town to navigate those issues. “Our previous proposal to paint the sidewalk in front of the school was understandably rejected due to the unaddressed safety issue that potentially may occur when the sidewalk becomes wet,” the GSA supervisors, Cindy Miller and Kendra Nesbitt wrote to the town. “We hope that this second proposal will alleviate some concerns and open up the conversation for other projects that the town may be interested in supporting.” The option selected by the committee and passed by council is to paint a rainbow strip along both sides of the sidewalk, leaving the large middle portion clear for pedestrians. In the proposal, the GSA explained that they have consulted with the manager of the Co-op Home Centre, who recommended using their porch and floor paint, which is slip resistant. The options passed over by the town include painting the same section of sidewalk, as was done last year; and painting a rainbow crosswalk across 6th Avenue where it intersects with Canawindra Cove. The GSA added that the latter option has the added benefit of drawing the driver’s attention to the fact that it is a busy crossing by the high school, as many students use this intersection. Jessica R. Durling, Local Journalism Initiative Reporter, Humboldt Journal
Toronto-based advertising agency The Brand Factory (TBF), digital agency Joey Ai, and digital content agency Caramel are honoured to receive awards of recognition from the Canadian Homebuilders' Association (CHBA) in three categories this year: Best Brochure, and Best Print Ad Campaign, for work with Kylemore Homes and its Angus Glen South Village community, as well as Best Virtual Tour Experience for work with Tridel and its MRKT Alexandra Park community.
BASKING RIDGE, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2021. John Koconis, Chairman and Chief Executive Officer of Timber, commented, “In the first quarter Timber continued to advance on all of its programs. In January, we announced that the Phase 2b CONTROL Study of Congenital Ichthyosis for our lead asset, TMB-001, had reached 50% enrollment. The Company anticipates topline data readout in the third quarter of 2021 for the TMB-001 study. The Phase 2b clinical trial evaluating TMB-002 (topical rapamycin) for the treatment of facial angiofibromas (FAs) in tuberous sclerosis complex (TSC) has made significant progress towards its clinical milestones as well. In March, our development partner on TMB-002, AFT Pharmaceuticals, entered into a licensing agreement for TMB-002 (trade name Pascomer®) in Europe with a third party. Under Timber’s agreement with AFT, Timber is entitled to a significant share of the royalties and milestones from the third party agreement and we believe that this provides further validation of our program. Also in January, we received confirmation that the U.S. Food and Drug Administration (“FDA”) had granted orphan drug designation for TMB-003, Timber’s locally delivered formulation of sitaxsentan, for the treatment of systemic sclerosis. All three of our programs now have orphan status and we expect continued progress on the clinical front, which is now being led by the Company’s new Chief Medical Officer, Alan Mendelsohn, M.D. who joined our team in January 2021. Timber ended the first quarter with $8.5 million cash and common shares outstanding of 36.7 million at March 31, 2021. We look forward to holding our first shareholder meeting as a public company on June 3rd, 2021 for shareholders of record as of April 12, 2021,” concluded Mr. Koconis. For Timber’s complete financial results for the period ended March 31, 2021, see the Company’s quarterly Form 10-Q filed with the Securities and Exchange Commission on May 11, 2021. About Timber Pharmaceuticals, Inc. Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma. For more information, visit www.timberpharma.com . Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. For more information, contact: Timber Pharmaceuticals, Inc. John Koconis Chairman and Chief Executive Officer email@example.com Investor Relations: Stephanie Prince PCG Advisory (646) 863-6341 firstname.lastname@example.org Media Relations: Adam DaleyBerry & Company Public Relations(212) email@example.com Jenna UrbanBerry & Company Public Relations(212) firstname.lastname@example.org - Tables Follow - Timber Pharmaceuticals, Inc. & SubsidiariesCondensed Consolidated Balance Sheets March 31, December 31, 2021 2020ASSETS(unaudited) Current assets Cash $ 8,500,053 $ 10,348,693Other current assets 291,929 377,290Total current assets 8,791,982 10,725,983Deposits 127,534 114,534Right of use asset 854,184 787,432Total assets $ 9,773,700 $ 11,627,949 LIABILITIES AND MEMBERS' AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 523,793 $ 395,049Accrued expenses 532,373 768,661Lease liability, current portion 278,059 217,651Total current liabilities 1,334,225 1,381,361Notes payable 37,772 37,772Lease liability 588,087 579,455Deferred tax liability 37,842 37,842Other liabilities 73,683 73,683Total liabilities 2,071,609 2,110,113 Commitments and contingencies (Note 8) Redeemable Series A convertible preferred stock, par value $0.001; 2,500 shares authorized; 1,819 shares issued and outstanding as of March 31, 2021 and December 31, 2020 1,945,692 1,909,805 Stockholders' equity Common stock, par value $0.001; 450,000,000 shares authorized; 36,659,685 shares issued and outstanding as of March 31, 2021, and 27,132,420 shares issued and outstanding as of December 31, 2020 36,660 27,132Additional paid-in capital 25,839,395 25,826,295Accumulated deficit (20,119,656) (18,245,396)Total stockholders' equity 5,756,399 7,608,031Total liabilities, redeemable convertible preferred stock, and stockholders' equity $ 9,773,700 $ 11,627,949 Timber Pharmaceuticals, Inc. & SubsidiariesCondensed Consolidated Statements of Operations(Unaudited) Three months ended March 31, 20212020 Grant revenues $ 40,734 $ 26,907 Operating costs and expenses Research and development 849,518 1,018,231Transaction costs - 1,189,842Selling, general and administrative 1,065,389 456,794Total operating expenses 1,914,907 2,664,867Loss from operations (1,874,173) (2,637,960) Other income (expense) Interest expense - (1,102,606)Interest income - 456,775Change in fair value of investment in BioPharmX - 83,560Change in fair value of warrant liability - (321,051)(Loss) gain on foreign currency exchange (87) 2,682Total other expense (87) (880,640)Net loss (1,874,260) (3,518,600)Accrued dividend on preferred stock units - (34,481)Cumulative dividends on Series A preferred stock (35,887) - Net loss attributable to common stockholders $ (1,910,147) $ (3,553,081)Basic and diluted net loss per share attributable to common stockholders $ (0.05) $ (0.56)Basic and diluted weighted average number of shares outstanding 35,079,143 6,295,724
Save big on the Nanit Pro baby monitoring system, which is $100 off at Amazon.
If the horse's positive test for the anti-inflammatory drug betamethasone is confirmed, Churchill Downs said it will strip Medina Spirit of its Kentucky Derby win and the racetrack has already banned Baffert from entering horses there. The controversy surrounding Medina Spirit's positive test raised questions about whether the three-year-old colt would be allowed to compete in the second leg of the Triple Crown.
FBI agents were at the sprawling site of a Hindu temple Tuesday as a lawsuit filed in federal court alleged workers from marginalized communities in India were lured to the U.S. and forced to work long hours for just a few dollars per day to help build the temple. The lawsuit accuses the leaders of the Hindu organization known as Bochasanwasi Akshar Purushottam Swaminarayan Sanstha, or BAPS, of human trafficking and wage law violations. An FBI spokesperson confirmed that agents were at the temple on “court-authorized law enforcement activity.” One of the attorneys who filed the suit said some workers had been removed from the site Tuesday. That attorney, Daniel Werner, called it “shocking that this happens in our backyard.” “It is even more disturbing that it has gone on for years in New Jersey behind the temple’s walls,” Werner, of Decatur, Georgia, said Tuesday outside the gates of the temple. “This is 200 workers who were behind these fences for sometimes a year or two years or even longer, paid about $1.20 an hour, working in hazardous conditions, not allowed to leave through these gates without being accompanied by somebody from BAPS.” The lawsuit says more than 200 workers — many or all of whom don't speak or understand English — were coerced into signing employment agreements in India over the last several years to work at the Hindu temple in Robbinsville, outside Trenton. They traveled under R-1 visas, which are meant for “those who minister, or work in religious vocations or occupations,” according to the lawsuit. When they arrived, the lawsuit says, their passports were taken away and they were forced to work at the temple from 6:30 a.m. to 7:30 p.m. with few days off, for about $450 per month. That wage works out to roughly $1.20 per hour. Of the $450, the workers allegedly only received $50 in cash per month, with the rest deposited into their accounts in India. The workers lived in a fenced-in compound where their movements were monitored by cameras and guards, according to the lawsuit, and they were told that if they left, police would arrest them because they didn't have their passports. Messages were left Tuesday at telephone numbers listed for BAPS in New Jersey. BAPS CEO Kanu Patel, who is named as a defendant in the lawsuit, told The New York Times: “I respectfully disagree with the wage claim.” A spokesperson for the organization, Lenin Joshi, disputed the allegations. “We are naturally shaken by this turn of events and are sure that once the full facts come out, we will be able to provide answers and show that these accusations and allegations are without merit,” Joshi told the Times. The lawsuit also names BAPS and several individuals described as having supervised the workers. It seeks unpaid wages and unspecified compensatory and punitive damages. ___ Associated Press writer Mike Catalini contributed to this report. David Porter, The Associated Press
Amy Bockerstette, 22, became the first person with Down syndrome to compete in a national collegiate athletic championship this week
Aberdeen Asia-Pacific Income Investment Company Limited (TSX: FAP) (the "Company"), a closed-end investment company trading on the Toronto Stock Exchange, announced today that it will pay a monthly distribution of CAD 2.25 cents per ordinary share on May 28, 2021 to all ordinary shareholders of record as of May 21, 2021 (ex-dividend date May 20, 2021).
The leadership candidate has said there will not be a single unionist party.
A rundown of the artists nominated for a Brit Award in 2021.
A trip to Connecticut for his Bellator debut led to Johnson being arrested on outstanding local charges.
CHERRY HILL, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company. The Company is pleased to announce that Jay Roberts, Chief Executive Officer, will present at BioNJ’s 11th Annual BioPartnering Conference. The presentation portion event is being held virtually from May 17-18, 2021. One-on-one partnering meetings will be held throughout the week (May 17-21 2021). An on-demand replay of Vyant Bio’s presentation will be available to registered guests. Conference Date: May 18-19, 2021 (Tuesday-Wednesday)Presentation Time:Tuesday, May 18, 2021 – 11:35am-1:05pm ET1:1 Partnering Meetings:May 17-21, 2021On-Demand Presentation:Available May 18-June 25, 2021 via the BioPartnering PortalRegistration: https://bionj.org/event/bionjs-11th-annual-biopartnering-conference Mr. Roberts will highlight the Company's updated business strategy, including significant aspects pertaining to the recent merger with StemoniX, Inc. He will also elaborate on the broader, going-forward corporate vision of Vyant Bio as it pertains to partnerships with biotech, large pharma, and the investment community. Additionally, Mr. Roberts will discuss the Company’s approach to identify unique therapeutics through the integration of novel human- derived biology with internally developed data science technologies and IND-enabling expertise. Vyant Bio will also be available for outside virtual 1:1 meetings both during and after BioNJ’s 11th Annual 33rd BioPartnering Conference. Please contact Jennifer K. Zimmons, Ph.D. email@example.com or +1 917.214.3514 for scheduling. ABOUT VYANT BIO, INC. Vyant Bio, Inc. (“Vyant Bio”) (Nasdaq: VYNT) is emerging as an advanced biotechnology drug discovery company. With capabilities in data, science (both biology and chemistry), engineering, and regulatory, we are rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. Leveraging these modalities, Vyant Bio is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. Vyant Bio operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Formerly known as Cancer Genetics, Inc., the company’s name was changed to Vyant Bio, Inc. in March 2021. Vyant Bio is headquartered in the US, with offices in Europe, and Australia. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to quickly and economically conduct research with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC-derived disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients. vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities. For more information, please visit or follow Vyant Bio at: Internet: www.vyantbio.com LinkedIn: https://www.linkedin.com/company/vyant-bio Twitter: @VyantBio Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s (formerly Cancer Genetics, Inc.) expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future collaborations and strategic transactions in this press release constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, achieve profitability and increase sales of our pre-clinical services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger with StemoniX, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements. Investor Contacts:Jennifer K. Zimmons. Ph.D.Investor RelationsZimmons International Communications, Inc.Email: firstname.lastname@example.orgPhone: +1.917.214.3514Source: Vyant Bio, Inc. ###
Lonestar Resources US Inc. (OTCQX: LONE) (including its subsidiaries, "Lonestar," "we," "us," "our" or the "Company") today reported financial and operating results for the three months ended March 31, 2021.
SAN FRANCISCO (AP) — California Gov. Gavin Newsom on Tuesday proposed $12 billion in new funding to get more people experiencing homelessness in the state into housing and to “functionally end family homelessness” within five years. “As governor I actually want to get something done. I don’t want to talk about this for a decade," he said at a former San Diego hotel that's been converted into housing for the homeless. Newsom's proposal includes $8.75 billion to expand a California program created during the pandemic that converts hotel and motel rooms and other properties into housing for people in need. Roughly half of that money would go toward creating housing where mental health and other behavioral services are provided on site to people living there. The nation’s most populous state has an estimated 161,000 people experiencing homelessness, which is more than any other state. Beyond the money for converting hotels, Newsom proposed spending $3.5 billion on new housing and rental support payments for families. If Newsom's plan wins support from the state Legislature, it's implementation would depend heavily on the willingness of local governments to go along. Local leaders showed support for the plan during the pandemic by converting 94 hotels, motels and other properties across the state into housing for people experiencing homelessness, said Jason Elliott, a Newsom adviser who works on housing and homelessness. Still, San Diego County Supervisor Nathan Fletcher, a fellow Democrat, acknowledged that tackling the issue is challenging and urged Californians to step up efforts to solve the politically difficult problem. “Every community group that you go to demands that you solve the problem of homelessness, and then in the exact same meeting they’ll demand you don’t solve it anywhere near them," he said. The new pending proposal came as part of a $100 billion pandemic recovery plan Newsom is rolling out this week. The massive amount comes from an astounding $76 billion estimated state budget surplus and $27 billion in new funding from the federal government’s latest coronavirus spending bill. Focusing on homelessness, a vexing issue for the state, could prove politically helpful for Newsom as he faces expected recall election later this year. A new state database shows that nearly 250,000 people sought housing services from local housing officials in 2020. Of that number, 117,000 people are still waiting for help while nearly 92,000 people found housing. Newsom — a former mayor of San Francisco, where the homelessness is very visible — seized the twin crises of homelessness and affordable housing even before the pandemic started last year. He launched projects “Roomkey” and “Homekey,” using federal funding to house homeless residents in hotels and motels during the pandemic and helped cities, counties and other local entities buy and convert motels and other buildings into housing. Newsom officials said $800 million spent on the program last year created 6,000 more housing units from motels, houses, dorms and other repurposed buildings, providing shelter for 8,200 people. The average cost to convert a unit into housing for people experiencing homelessness was nearly $150,000, Newsom administration officials said at a recent briefing. They said that is much cheaper than building housing from scratch. Local leaders have welcomed Newsom's focus on the problem. Big city California mayors are seeking $20 billion from the state over five years to address housing and homelessness. Advocates for the homeless say there's simply not enough affordable housing to help people who slip into homelessness, which is why tent camps and sleeping bags still clutter highway ramps and city sidewalks. A February audit criticized the state for its fragmented approach to addressing homelessness, and urged the state to track spending and set statewide policy. It identified at least nine state agencies that spent $13 billion on 41 programs to address homelessness without evidence to show what was effective. —— Associated Press writer Kathleen Ronayne contributed from Sacramento, California. Janie Har, The Associated Press
A spokeswoman for Tiffany said her “experience with the Secret Service was entirely professional” and that reports otherwise were “nothing more than gossip”
I have never been someone who Does Her Hair. The length has varied, and occasionally veered into impersonating Timothée Chalamet, but the most exciting I’ve really got styling-wise is a hairdryer (or hair gel, once in a blue moon). For the most part, I wash it and I air-dry it and that’s that. This is due to laziness more than anything else, but also being unwilling to spend money on hair tools I haven’t used since I was 13 and had Gerard Way posters on my walls. Styling your hair took time, money, effort, and probably some forehead burns — so I wasn’t about it, thanks very much. But over the course of the pandemic, something shifted for me. I stopped making an effort and slobbed around like the best of them. After a while, though, it left me feeling adrift. I wanted to do something with myself that would pull me out of this three-day pajama funk and make me feel put together. I’ve always been pretty pared back when it comes to makeup (the goal is clear, clean skin, a little blush, brows, and lipstick on a Big Day) so I wasn’t feeling a clown-makeup fantasy. Outfits-wise, I’m happy to take it slow and gently reintroduce my post-lockdown body to the concept of waistbands and bras. But when it comes to hair, I’m finally ready for a style that looks effortless but isn’t. And the putting it together is part of the fun. My inspiration for this has come in part from my recent immersion in period dramas and historical dress. As a lesbian, I have dutifully watched every queer women period drama that’s been released in recent years (Colette, Portrait Of A Lady On Fire, The World To Come), which reintroduced me to a world of queer coding in clothing and style. I wanted to immerse myself in queer readings of historical fashion where short hair was an act of rebellion popularized by queer and lesbian women. Unlike modern queer coding through hair, which is bound up in styles like undercuts and mullets, I wanted to escape into more vintage looks. Like the queer women who defined and explored fashion and beauty trends in the last century, I wanted to find a balance between looking effortless and looking done, which strays far enough from conventional conceptions of modern femininity that it’s like a non-verbal if you know, you know. It led me down the rabbit hole of compulsively watching videos like “I Tried Following A Real Edwardian Hair Care Routine”, “Attempting 100 Years Of Victorian Hair!” and “cutting my hair off cause I want to look like a 30s movie star” to try and find the look I was after. And then The Dig came out in January of this year and my search was over. The film was long and boring and I loved it, but my favorite part was Carey Mulligan‘s soft, wavy bob. It looked done but disheveled, old-fashioned but with enough movement to be modern, and I was obsessed with it. Which is how I ended up, mask on in a salon chair, at London’s Gielly Green with artistic director Skye Edwards, talking through the Carey Mulligan haircut I’d fixated on for months. Unfortunately for me, Carey and I have very different hair types: We both have naturally straight hair, but mine is almost aggressively thick. In my naivety I’d hoped that a haircut in and of itself would make it wavy; I was obviously delusional. Edwards quickly (and kindly) reminded me that styling is integral to a look like this, and the cut was designed to look good both styled (if I’m feeling adventurous) and more like a modern French bob when straight. This meant short at the back of the neck and chin length, with some softening layers around the head and framing the face. After cutting once when wet and again when dry, Edwards went in to style using a barrel brush and hairdryer, shaping the waves to look done but not too done. By the time she’d finished, my hair was the spitting image of Carey’s before she gets all windswept watching Ralph Fiennes dig up a ship. For the next couple of days I was obsessed with the results, which made me feel like my granny but also, when I put on a beret, like a 1940s evacuee. But after the first wash, I was brought back down to earth as I worked to find new ways to style it straight. After a few washes, I’ve now decided I’ll rotate between blowdrying straight and curling with a wand, sectioning hair and curling pieces a mix of towards and away from the face to achieve a more natural look. Unlike the cut on the day, which was deliberately set and verging on granny chic (which is absolutely my special-occasion vibe), day-to-day wear is a bit more modern, chaotic, and 1920s. It’s perfect for my post-lockdown life as someone who Does Her Hair — but still doesn’t put that much effort into it. This story was originally published on Refinery29 UK. Like what you see? How about some more R29 goodness, right here?